Operating through 106 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 285,000 TMS treatments to over 8,000 patients struggling with depression.
October 8, 2019 – Toronto, ON –
GREENBROOK TMS ANNOUNCES DATES FOR ITS THIRD QUARTER 2019 FINANCIAL RESULTS
September 26, 2019 – Toronto, ON –
GREENBROOK TMS ANNOUNCES CLOSING OF ACQUISITION OF ACHIEVE TMS
September 11, 2019 – Toronto, ON –
GREENBROOK TMS TO ACQUIRE ACHIEVE TMS
August 6, 2019 – Toronto, ON –
GREENBROOK TMS CONTINUES EXECUTION OF GROWTH STRATEGY AND REPORTS RECORD SECOND QUARTER FINANCIAL RESULTS
July 9, 2019 – Toronto, ON –
GREENBROOK TMS ANNOUNCES DATES FOR ITS SECOND QUARTER 2019 FINANCIAL RESULTS
June 28, 2019 – Toronto, ON –
GREENBROOK TMS ANNOUNCES RESULTS OF VOTING AT ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS
May 17, 2019 – Toronto, ON –
GREENBROOK TMS COMPLETES C$30 MILLION BOUGHT DEAL PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT
